Share Name Share Symbol Market Type Share ISIN Share Description
Ekf Diagnostics Holdings Plc LSE:EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.00 -2.22% 44.00 43.70 44.30 44.40 43.80 44.00 1,157,157 16:35:28
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 81.8 21.4 3.5 12.7 200

Ekf Diagnostics Share Discussion Threads

Showing 3926 to 3949 of 4525 messages
Chat Pages: Latest  169  168  167  166  165  164  163  162  161  160  159  158  Older
Or someone who's amused at the ego of A clueless punter like you - no matter that the market is not acting right for a year - who is convinced the world is wrong and he is right.
pscyhologically only someone who has lost money in a share will continue to come back to it hoping to recoup the gains.

This will be the second time you will have lost money on a trade - just from the ones you conveniently declare. First being SDI.

EKF will be higher from it's 80p, come calendar YE IMHO

thank you wan. PS. Any idea when the share price will finally see your insights and finally take off? Might be a bit more helpful.
Just a quick update -

At-home Testing tab now added to EKF's USA website -

ADL Health "now part of the EKF Diagnostics Group"

Very much looking forward to the expansion/increased range of tests across a broader suite of healthcare applications!

Phew- morning wan.
Most readers already know, and indeed 'appreciate', that EKF has a Preferred Partnership Agreement (PPA) with Mount Sinai Innovation Partners (MSIP) that provides EKF and ultimately its shareholders with advanced access to innovative commercial opportunities arising from Mount Sinai Health System owned technologies, managed by MSIP, in the field of healthcare technologies. So, it's is encouraging that Mount Sinai are still aiming high with transformative actions and investment at scale, to include novel diagnostics with the overarching goal of positively impacting patients’ health -

Press Release
Mount Sinai Launches Department of Artificial Intelligence and Human Health
New department is the first of its kind at a U.S. medical school

New York, NY (October 11, 2021)

The Icahn School of Medicine at Mount Sinai has launched a new department dedicated to advancing artificial intelligence (AI) to transform health care, further positioning the Mount Sinai Health System as a leader in providing patient care through pioneering innovations and technologies. The Department of Artificial Intelligence and Human Health is the first department of its kind within a medical school in the United States.

The department’s mission is to lead the artificial intelligence-driven transformation of health care through innovative research, apply that knowledge to treatment in hospital and clinical settings, and provide personalized care for each patient, which will expand Mount Sinai’s impact on human health across the Health System and around the world.

“Mount Sinai’s AI enterprise and its collective entities will be the connective fabric linking and integrating our work throughout the entire Health System, as we robustly collaborate with all our institutes, departments, and centers to provide phenomenal patient care,” said Thomas J. Fuchs,, Dean for Artificial Intelligence and Human Health, Co-Director of the Hasso Plattner Institute for Digital Health at Mount Sinai, and Professor of Computational Pathology and Computer Science in the Department of Pathology at Icahn Mount Sinai. “The overarching goal of the Department for AI and Human Health is to impact patients’ health with AI. We will accomplish this by building AI systems at scale from data representing Mount Sinai’s diverse patient population. These systems will work seamlessly across all hospitals and care units to support physicians, foster research, and most importantly help patients' care and well-being.”

Dr. Fuchs, who will lead the Department, is a prominent scientist in the groundbreaking field of computational pathology, with decades of experience in machine learning and artificial intelligence in health care. Together with his team, he will guide the department in creating an “AI Fabric” that will integrate machine learning and AI-driven decision-making throughout the Health System’s eight hospitals. This effort will include creating a hub-and-satellite model to make new tools and techniques available to all Mount Sinai physicians, and building an infrastructure for high-performance computing and data access to improve Mount Sinai's diagnostic and treatment capabilities.

The new department continues to build on Mount Sinai’s expertise and early adaptation of various forms of artificial intelligence, including machine learning to develop novel diagnostics and treatments for diseases. Earlier this year, Icahn Mount Sinai announced it will offer a new PhD concentration in Artificial Intelligence and Emerging Technologies in Medicine as part of its PhD in Biomedical Sciences program starting in the fall of 2022. The concentration will train future scientists in cutting-edge technologies, including AI, medical devices, robotic machines, and sensors. The Hasso Plattner Institute for Digital Health at Mount Sinai—a collaboration between the Hasso Plattner Institute for Digital Engineering in Potsdam, Germany, and the Mount Sinai Health System—formed in 2019 to expand capabilities and create new tools of data science, biomedical and digital engineering, machine learning, and AI, including wearable technology.

Full release - hTTps://

Do we think wan's previous daily enthusiasm is running on fumes now?
In light of such excellent results can anyone explain why the market is not giving a you know what about it all? Answer: markets are a forward looking mechanism and they continuously anticipate the future. In other words fellas - what some consider good news it has been priced in long ago.
The CFP SDL Free Spirit Fund run by Keith Ashworth-Lord has just sent out its October factsheet. EKF are the fourth largest holding at 3.91% of the portfolio, and they have this to say:

"EKF Diagnostics reported an excellent set of interim results which saw sales increase by 47% and operating profit by 72%. The core point-of-care diagnostics business is returning to pre-pandemic levels while Covid-19 testing demand remains strong.

Encouragingly, these windfall profits are being reinvested into building a much broader contract manufacturing and molecular diagnostics business to serve non-Covid related demand. Crucially, this expansion is customer-led as EKF’s large private sector partner increasingly moves into healthcare. The acquisition of ADL Health, a US testing laboratory, is strategically important as it positions EKF as a single provider able to encompass all products and services from ‘sample-to-result’."

Only thing you need it to dovetail well with is the share price old chap. Not being funny just amazed folks can be stuck for years in their own thesis and fail to answer the question: why is the market not validating my thesis? Is there anything I am missing (Charlie Munger's favourite question, if you like)?
Edit to the above post - And in turn dovetails rather well with the new laboratory testing capability and capacity.
Recall that EKF is already manufacturing enzyme products (including at least one in the article below, salicylate hydroxylase) and they are investing to increase fermentation capacity to drive aggressive organic growth, plus they are collaborating on a new molecular enzyme product for their private sector partner to be made in Elkhart.

I was thus keen to understand and gain at least some elementary background information on enzyme use and future prospects etc. So, I thought the following article, which is not too demanding, might of interest to others too.

Readers will also note that sample collection is paramount in terms of contamination and storage/transport etc, which could dovetail rather nicely with other EKF products and indicates they have potential utility 'beyond' that for Covid-19 testing (which EKF have been saying for some time). And in turn dovetails rather well with the new laboratory testing capability and capacity.

Excepts follow if you don't want to read the whole article -

An overview of three biocatalysts of pharmaceutical importance synthesized by microbial cultures
Divakar Dahiya , Poonam Singh Nigam ,
Biomedical Sciences Research Institute, Ulster University, Coleraine Northern Ireland, UK
Received: 08 March 2021 Accepted: 24 April 2021 Published: 27 April 2021

The main disadvantages in the use of conventional analytical diagnosis methods are: first of all the precautions should be taken during the collection of samples by patients at home or by staff at care centers to maintain the sterility and avoid any contamination; secondly, sending required quantity of samples under proper storage conditions to pathology labs, without any spillage during transportation; thirdly the analytical methods of testing must be performed in a properly equipped laboratory setting. That requires the availability of qualified skilled biomedical scientists and pathologists to perform these lab-based analytical testing using conventional methods. There are several important enzymes, which could be used for different assays, have been studied for their biosynthesis employing selective microorganisms

In this article, we have included the published information on enzymes used in diagnostic assays and in biotransformation of drugs, which are of pharmaceutical importance, and those have been studied for their biosynthesis using specific microbial strains. These enzymes have their application as an effective and prudent tool in biomedical and pharmaceutical sector, as discussed in following sections.

3. Conclusion and future perspectives
With a change in lifestyle and an increasing ageing population in many countries, diseases and health-disorders are also increasing. Therefore, accurate test methods results are needed to deal with the increasing number of health issues, and for the timely treatment of a particular diagnosed condition. Different enzymes, diagnostic kits and biosensors are being evaluated for monitoring and diagnosis of the types of suspected ailments. Diagnostic tests have been widely used to detect and quantify different biomarkers to attain the critical information about health care, which is an important step in making accurate medical decisions. The major challenges with use of enzymes for diagnostic purposes are their yield, shelf life and the stability, if these enzymes were extracted from non-microbiological sources, such as animal tissues.

Several diagnostic methods used in pathology labs require costly reagents, equipment, and time for analysis of samples, as well as the availability of trained pathologists and technical staff to operate the process. Hence, there is a focus on research and development of tools that are cost-effective, stable and simple-to-operate. The enzyme-based detection of various health disorders have been investigated and in some cases it is fully established; but high costs are involved in enzyme production, purification, their shelf life and storage conditions. For an economical production of enzymes by a humane technique (avoiding their extraction from animal tissues), the use of microbial fermentation technology is a preferred option. Enzymes synthesized by selected microbial strains can be purified for high specific activities and characterized for their stability. Such bioactive enzyme preparations, either in a free-state or in an immobilized-state, can be utilised for diagnostic purposes with specificity and accuracy.


One would imagine that certain investors (ESG?), and indeed companies, would like the fact that EKF are using humane techniques (avoiding their extraction from animal tissues), with the use of microbial fermentation technology being the preferred option.

Food (or next generation natural ingredients) for thought at least!

Mg - can you remind us what's your 12 month paper return as of today?
Folks believe what they want to believe. Wan - surprise as and become unpredictable for once:)
As James said further above, it was expected and was for the reason previously explained. And we were also told the reduction is not a burning issue as such.

Therefore and from my perspective as an investor, it is notable that the demand is there. Put another way, we have an expected but patient seller and relatively strong demand. So I don't see the shares falling back much, as the same buyers can now also pick up the shares on the resulting dip at a discount.

So, perhaps it's worth recalling Singer's headlines to its research note on EKF -

'EKF recently unveiled a strategy for driving growth in the business over the next few years. It will be led by a refreshed executive management team and board, building on renewed strength in the core business and opportunities in developing wider contract development and manufacturing activities. Accretive bolt-on acquisitions will also be considered, all funded by the current strong net cash position of the group. Overall, the ambition is to deliver sustainable double-digit EBITDA growth into the medium term. This note takes a detailed look at the growth drivers and opportunities now in prospect. In addition to introducing conservative formal FY22 & FY23 estimates for the first time, we also look at a range of potential scenarios, one of which shows how EBITDA could reach £45.9m by FY24. Putting that on a multiple of 13- 15x implies a potential Enterprise Value of £597-688m, against a current EV of £314m. Successful delivery should therefore lead to material value creation.'

Not to mention that there is apparently another investment and spinout in the wings.

I see fresh waves of selling about to come mg's way so guess he's happy?One wonders why cm sold at the high? Will he do the same foi NJF forward? Like I said earlier the price he has sold at is quite smth.
It has been well known for ages that Christopher Mills needs to reduce his holdings in EKF, as they constitute a disproportionately large part of the fund holdings. Further disposals are bound to follow and all shareholders are aware (or should be aware) of that.
And here we go - director's money bailing out.

it's not the no of shares but rather the price they have sold out at which speaks a fair bit about their expectations.

Agreed most market makers wouldn't be able to trade if their lives would depend on it (were it not for the order flow). Re PI's - I would disagree. Even though it's their money on the line 9/10 just doesn't cut it (not for lack of iq per se but rather knowledge of the game). Hence the passive trackers have had tremendous growth over the years. Otherwise why bother?Good luck pal.
Market makers never play ball its fixed, you have to use experience on how to deal with their games.
Trust your judgment and experience it seems to work you have made good calls, stand back from it a bit and see the bigger picture.
Pi,s are the real clever ones for they use own money, unlike some larger city traders who have information that we can only dream of and salary to match.
IF they were as good as they say they are then why do they not go it ALONE!

Can't disagree with most of your comments. Yes I do look into things daily out of necessity rather than choice. As one of the best ever in this business used to say ... one needs to have a long term horizon for reaping the gains but a very short one for risk.
The old saying "let the trend be your friend" is good advice for long term gains.
The share price has performed well in last 2 years, plus spin offs.
Perhaps tong is a bit sensitive on daily activity of charts, i was like that once many many years ago during dot com boom.
Current levels around 84p is about right and may touch late 70,s from time to time.
Market makers are there to bend and twist the arms of holders and sellers alike to make a market, i had a brother like that you get used to it you know.
But then again one could be wrong with the above Exciting isn't it!.

Fact 3. The share price is the ultimate fundamental (as it represents the equilibrium of demand and supply for shares). Regardless what a few retail players think (fundamentals are), the market is clearly telling you there is zero buying power to push the share price up (aka not enough buyers buying into wan's thesis). 12 months and counting - why? This is the ultimate question that matters in this game and I never see it raised on the board:)Consequently, either the entire market is wrong or wan and co of the world are. Beeen long enough in this business to know that the market only giveth (and taketh). No disrespect to anyone honestly (as some of you know I just bailed out of a long position with a minor loss on here) - all I am saying is wake up and smell the coffee if the market doesn't play ball to one's particular thesis. Usually there is a reason behind that. Ps. If there is another b/o I will be willing to try again but until then I'd rather respect Mr Market as I am perfectly aware I shouldn't play macho with him.
Fwiw, I think the pandemic has acted as an accelerant in terms of the evolution of the diagnostic industry. This rapid evolution is not limited to just the diagnostic industry players themselves, with patients and health consumers seeking to move away from traditional settings such as clinics and hospital towards the home and/or telehealth settings.

In this regard, I strongly believe that EKF's recent acquisition is indeed part of this evolution towards a 'much' wider offering in terms of testing and screening and the manufacture of a wide range of testing kits that will help make care more accessible, thus positioning EKF as a player in this evolution by becoming a single provider able to encompass all products and services from 'sample-to-result'. Indeed as EKF's CEO, Mike Salter's commented -

Mike Salter, President of EKF Diagnostics' Americas and Chief Executive Officer Designate of EKF, commented: "We are delighted to have agreed terms for the acquisition of ADL Health and believe this represents a highly attractive and earnings accretive transaction. Strategically this is an excellent move for us as it positions EKF as a leading provider of diagnostic products and services, including a testing offering that our industry partners have been looking for us to provide."

"The ability to offer testing for a wide range of diseases, combined with our existing point-of-care device, reagent, sample collection, kitting and manufacturing services, positions us as a single provider able to encompass all products and services from 'sample-to-result'."

So, test kit manufacturing addressing a far wider spectrum of disease is only one element, and although it's obviously an initial phase, the lab acquisition is obviously ready-to-go! Cue also, Renalytix, Verici and Trellus Health, and EKF's industry partners.

Clearly there is more yet to be done in terms of delivery of the growth strategy (and reported accordingly), but it's also clear that EKF is not suffering from inertia! And it's up to investors to read into this early phase of EKF's growth strategy, and indeed the impact from the pandemic on the evolution of diagnostic testing, as they see fit.

Chat Pages: Latest  169  168  167  166  165  164  163  162  161  160  159  158  Older
Your Recent History
Ekf Diagno..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20221206 01:51:09